OCC Stock Overview
A regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia, the United States, the United Kingdom, and the European Union. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Orthocell Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.61 |
| 52 Week High | AU$0.77 |
| 52 Week Low | AU$0.35 |
| Beta | 0.85 |
| 11 Month Change | -15.86% |
| 3 Month Change | 67.12% |
| 1 Year Change | 50.62% |
| 33 Year Change | 15.09% |
| 5 Year Change | 1.67% |
| Change since IPO | 69.44% |
Recent News & Updates
Recent updates
Companies Like Orthocell (ASX:OCC) Are In A Position To Invest In Growth
Sep 09
It's Probably Less Likely That Orthocell Limited's (ASX:OCC) CEO Will See A Huge Pay Rise This Year
Oct 25We Think Orthocell (ASX:OCC) Can Afford To Drive Business Growth
Nov 16We're Not Very Worried About Orthocell's (ASX:OCC) Cash Burn Rate
Jul 29Orthocell (ASX:OCC) Is In A Good Position To Deliver On Growth Plans
Mar 23We're Not Worried About Orthocell's (ASX:OCC) Cash Burn
Dec 08Here's Why We're Not At All Concerned With Orthocell's (ASX:OCC) Cash Burn Situation
May 31Companies Like Orthocell (ASX:OCC) Are In A Position To Invest In Growth
Feb 15How Does Orthocell's (ASX:OCC) CEO Salary Compare to Peers?
Dec 24Shareholder Returns
| OCC | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | -4.7% | -3.6% | 1.5% |
| 1Y | 50.6% | 10.0% | 17.2% |
Return vs Industry: OCC exceeded the Australian Biotechs industry which returned 10% over the past year.
Return vs Market: OCC exceeded the Australian Market which returned 17.2% over the past year.
Price Volatility
| OCC volatility | |
|---|---|
| OCC Average Weekly Movement | 10.4% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 8.6% |
| 10% most volatile stocks in AU Market | 17.3% |
| 10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: OCC has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: OCC's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | n/a | Paul Anderson | orthocell.com |
Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia, the United States, the United Kingdom, and the European Union. The company offers Ortho-ATI, a cell therapy for treatment of chronic tendon injuries; Striate+, a resorbable collagen membrane used for guided bone and tissue regeneration in dental procedure; Remplir, a collagen scaffold used in peripheral nerve repair; and Ortho-ACI, an autologous chondrocyte implantation to treat articular cartilage defects in the knee and ankle. Orthocell Limited was incorporated in 2006 and is headquartered in Murdoch, Australia.
Orthocell Limited Fundamentals Summary
| OCC fundamental statistics | |
|---|---|
| Market cap | AU$149.45m |
| Earnings (TTM) | -AU$7.18m |
| Revenue (TTM) | AU$5.32m |
27.4x
P/S Ratio-20.3x
P/E RatioIs OCC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OCC income statement (TTM) | |
|---|---|
| Revenue | AU$5.32m |
| Cost of Revenue | AU$1.63m |
| Gross Profit | AU$3.69m |
| Other Expenses | AU$10.87m |
| Earnings | -AU$7.18m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.03 |
| Gross Margin | 69.39% |
| Net Profit Margin | -135.10% |
| Debt/Equity Ratio | 0% |
How did OCC perform over the long term?
See historical performance and comparison